Intensity-modulated radiotherapy for prostate cancer

被引:42
作者
Fischer-Valuck, Ben W. [1 ]
Rao, Yuan James [1 ]
Michalski, Jeff M. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63130 USA
关键词
Prostate cancer; intensity-modulated radiation therapy (IMRT); CONFORMAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CONVENTIONALLY FRACTIONATED RADIOTHERAPY; RECTAL DOSE REDUCTION; PHASE-III TRIAL; PROSPECTIVE MULTICENTER; BIOCHEMICAL CONTROL; NON-INFERIORITY; 78; GY;
D O I
10.21037/tau.2017.12.16
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Radiation therapy (RT) is a curative treatment modality for localized prostate cancer. Over the past two decades, advances in technology and imaging have considerably changed RT in prostate cancer treatment. Treatment has evolved from 2-dimensional (2D) planning using X-ray fields based on pelvic bony landmarks to 3-dimensional (3D) conformal RT (CRT) which uses computed tomography (CT) based planning. Despite improvements with 3D-CRT, dose distributions often remained suboptimal with portions of the rectum and bladder receiving unacceptably high doses. In more recent years, intensity-modulated radiation therapy (IMRT) has become the standard of care to deliver external beam RT. IMRT uses multiple radiation beams of different shapes and intensities delivered from a wide range of angles to ` paint' the radiation dose onto the tumor. IMRT allows for a higher dose of radiation to be delivered to the prostate while reducing dose to surrounding organs. Multiple clinical trials have demonstrated improved cancer outcomes with dose escalation, but toxicities using 3D-CRT and escalated doses have been problematic. IMRT is a method to deliver dose escalated RT with more conformal dose distributions than 3D-CRT and has been associated with improved toxicity profiles. IMRT also appears to be the safest method to deliver hypofractionated RT and pelvic lymph node radiation. The purpose of this review is to summarize the technical aspects of IMRT planning and delivery, and to review the literature supporting the use of IMRT for prostate cancer.
引用
收藏
页码:297 / 307
页数:11
相关论文
共 57 条
[1]   Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial [J].
Aluwini, Shafak ;
Pos, Floris ;
Schimmel, Erik ;
Krol, Stijn ;
van der Toorn, Peter Paul ;
de Jager, Hanja ;
Alemayehu, Wendimagegn Ghidey ;
Heemsbergen, Wilma ;
Heijmen, Ben ;
Incrocci, Luca .
LANCET ONCOLOGY, 2016, 17 (04) :464-474
[2]  
[Anonymous], 2016, ADV RADIAT ONCOL
[3]   Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms [J].
Boersma, LJ ;
van den Brink, M ;
Bruce, AM ;
Shouman, T ;
Gras, L ;
te Velde, A ;
Lebesque, JV .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :83-92
[4]  
Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6
[5]   Fractionation and protraction for radiotherapy of prostate carcinoma [J].
Brenner, DJ ;
Hall, EJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (05) :1095-1101
[6]   Intensity-modulated radiation therapy: Supportive data for prostate cancer [J].
Cahlon, Oren ;
Hunt, Margie ;
Zelefsky, Michael J. .
SEMINARS IN RADIATION ONCOLOGY, 2008, 18 (01) :48-57
[7]   Hypofractionated radiotherapy for prostate cancer [J].
Dearnaley, David ;
Hall, Emma .
LANCET ONCOLOGY, 2016, 17 (12) :E518-E518
[8]   Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial [J].
Dearnaley, David ;
Syndikus, Isabel ;
Sumo, Georges ;
Bidmead, Margaret ;
Bloomfield, David ;
Clark, Catharine ;
Gao, Annie ;
Hassan, Shama ;
Horwich, Alan ;
Huddart, Robert ;
Khoo, Vincent ;
Kirkbride, Peter ;
Mayles, Helen ;
Mayles, Philip ;
Naismith, Olivia ;
Parker, Chris ;
Patterson, Helen ;
Russell, Martin ;
Scrase, Christopher ;
South, Chris ;
Staffurth, John ;
Hall, Emma .
LANCET ONCOLOGY, 2012, 13 (01) :43-54
[9]   Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial [J].
Dearnaley, David P. ;
Sydes, Matthew R. ;
Graham, John D. ;
Aird, Edwin G. ;
Bottomley, David ;
Cowan, Richard A. ;
Huddart, Robert A. ;
Jose, Chakiath C. ;
Matthews, John H. L. ;
Millar, Jeremy ;
Moore, A. Rollo ;
Morgan, Rachel C. ;
Russell, J. Martin ;
Scrase, Christopher D. ;
Stephens, Richard J. ;
Syndikus, Isabel ;
Parmar, Mahesh K. B. .
LANCET ONCOLOGY, 2007, 8 (06) :475-487
[10]   Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial [J].
Dearnaley, DP ;
Khoo, VS ;
Norman, AR ;
Meyer, L ;
Nahum, A ;
Tait, D ;
Yarnold, J ;
Horwich, A .
LANCET, 1999, 353 (9149) :267-272